Clinical Trial Update: Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety and efficacy data for Voxzogo (vosoritide) in growth deficits associated with Morquio A syndrome (MPS IVA) and Marotea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Maroteaux-lamy Syndrome
• Morquio Syndrome

Drugs mentioned

• VOXZOGO (VOSORITIDE)

Snippet

Sponsor: University of California, San Francisco | Conditions: MPS IVA, MPS VI | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING